United Therapeutics (UTHR) CFO sells 10,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On April 20, 2026, he exercised 10,000 stock options at $135.42 per share to acquire common stock, then sold 10,000 shares in open‑market trades at prices ranging from about $571.79 to $585.80. The filing shows he now directly holds 18,876 shares of common stock. The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($5,778,607)
Net Sell
15 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.78M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 880 | $572.328 | $504K |
| Sale | Common Stock | 1,543 | $573.4489 | $885K |
| Sale | Common Stock | 442 | $574.0874 | $254K |
| Sale | Common Stock | 1,010 | $575.4068 | $581K |
| Sale | Common Stock | 1,398 | $576.3746 | $806K |
| Sale | Common Stock | 687 | $577.2684 | $397K |
| Sale | Common Stock | 500 | $578.9039 | $289K |
| Sale | Common Stock | 340 | $579.8644 | $197K |
| Sale | Common Stock | 488 | $581.662 | $284K |
| Sale | Common Stock | 983 | $582.4695 | $573K |
| Sale | Common Stock | 1,009 | $583.5454 | $589K |
| Sale | Common Stock | 482 | $584.494 | $282K |
| Sale | Common Stock | 238 | $585.3622 | $139K |
Holdings After Transaction:
Stock Option — 72,500 shares (Direct, null);
Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $571.79 to $572.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $572.86 to $573.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $573.90 to $574.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.92 to $575.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.92 to $576.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $576.94 to $577.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.26 to $579.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $579.27 to $580.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $581.01 to $582.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $582.02 to $583.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $583.035 to $584.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $584.05 to $585.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $585.09 to $585.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Option exercise: 10,000 shares
Option strike price: $135.42 per share
+4 more
7 metrics
Shares sold
10,000 shares
Common stock sold in open-market trades on April 20, 2026
Option exercise
10,000 shares
Stock options exercised into common stock on April 20, 2026
Option strike price
$135.42 per share
Exercise price for 10,000 stock options
Sale price range
$571.79–$585.80 per share
Price ranges noted across multiple sale footnotes
Shares held after
18,876 shares
Direct common stock ownership after transactions
Largest line-item sale price
$585.3622 per share
Highest weighted-average price shown among individual sale entries
Derivative options remaining
0 for this grant
DerivativeSummary empty after exercising 10,000-share option
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did UNITED THERAPEUTICS (UTHR) report for its CFO?
UNITED THERAPEUTICS reported that CFO James Edgemond exercised 10,000 stock options and sold 10,000 common shares. The activity occurred on April 20, 2026, as open‑market sales disclosed in a Form 4 insider trading report.
Did the UNITED THERAPEUTICS (UTHR) CFO exercise stock options in this Form 4?
Yes. The Form 4 shows James Edgemond exercised stock options for 10,000 shares of UNITED THERAPEUTICS common stock at a strike price of $135.42. A corresponding derivative entry reflects the option exercise, reducing his remaining option position for that grant.
Were the UNITED THERAPEUTICS (UTHR) CFO’s trades made under a Rule 10b5-1 plan?
Yes. A footnote explains that the option exercise and subsequent share sales were executed under a Rule 10b5-1 trading plan. The plan was entered into by the reporting person on October 31, 2025, indicating the trades were pre‑arranged rather than newly timed.
What type of signal does this UNITED THERAPEUTICS (UTHR) Form 4 send to investors?
The Form 4 shows a routine exercise-and-sell pattern: 10,000 options exercised, then 10,000 shares sold. Because the transactions occurred under a pre‑planned Rule 10b5-1 arrangement, the timing carries limited informational value about the CFO’s short‑term view on UTHR.